Investigational neurostimulation device aims to reduce stroke damage

Nov 17, 2009

(PhysOrg.com) -- Stroke researchers at the Methodist Neurological Institute in Houston are the only ones in Texas to offer a novel device that might extend the acute stroke treatment window from three hours to 24.

The miniature neurostimulator, about the size of a staple, is implanted near the sphenopalatine ganglion, a nerve located in the roof of the patient’s mouth, within 24 hours of the onset of . The minimally takes less than 30 minutes and is performed under .

Pioneered by an Israeli-based company called Brainsgate, a donut-shaped transmitter is placed on the patient’s cheek near the implanted device. A steady stream of is delivered for several hours a day over a five-day period. The neurostimulator is then removed from the patient’s mouth.

“Neurostimulation has been successfully used for years in patients with epilepsy,” said Dr. David Chiu, medical director of the Eddy Scurlock Stroke Center and the study’s primary investigator at Methodist. “We know that stimulating the sphenopalatine ganglion can dilate arteries so that more blood flow is delivered to the stroke-affected hemisphere of the brain.”

The trial, called impact-24 (Implant for Augmentation of CBF Trial in a 24 hour window), is a multi-center, randomized, double blind study taking place over the next two years. Methodist is one of six locations in the United States to offer this feasibility study. If study results are favorable, the may broaden the trial to include more U.S. patients.

Stroke is the third leading cause of death and the leading cause of long-term adult disability in the United States. Ischemic stroke, or a blood clot to the brain, affects 750,000 Americans each year. The only current FDA-approved treatment is tPA, but the drug must be administered within three hours of symptom onset.

Provided by Methodist Hospital System

Explore further: Fruit fly study identifies brain circuit that drives daily cycles of rest, activity

add to favorites email to friend print save as pdf

Related Stories

Not a moment to lose in therapy for acute stroke

Sep 24, 2008

In an editorial response to a report in the September 25 issue of the New England Journal of Medicine on the efficacy of intravenous thrombolysis treatment in the hours after acute ischemic stroke, Patrick Lyden, M.D., profes ...

Arrival method, slow response often delay stroke care

Aug 08, 2008

Most stroke patients can't recall when their symptoms started or do not arrive at the hospital in a timely manner, so they cannot be considered for time-dependent therapies such as the clot-busting drug tissue plasminogen ...

Study opens way for later treatment of acute stroke

Sep 15, 2008

The time span in which treatment should be given for acute ischaemic stroke – i.e. stroke caused by a clot or other obstruction to the blood supply – can be lengthened. This according to a study from the Swedish medical ...

Recommended for you

Controlling brain waves to improve vision

12 hours ago

Have you ever accidentally missed a red light or a stop sign? Or have you heard someone mention a visible event that you passed by but totally missed seeing?

Study suggests targeting B cells may help with MS

13 hours ago

A new study suggests that targeting B cells, which are a type of white blood cell in the immune system, may be associated with reduced disease activity for people with multiple sclerosis (MS). The study is released today ...

Paying closer attention to attention

17 hours ago

Ellen's (not her real name) adoptive parents weren't surprised when the school counselor suggested that she might have attention deficit hyperactivity disorder (ADHD).

User comments : 0

More news stories

Google+ boss leaving the company

The executive credited with bringing the Google+ social network to life is leaving the Internet colossus after playing a key role there for nearly eight years.